Welcome to our dedicated page for Centessa Pharmaceuticals plc American Depositary Shares news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals plc American Depositary Shares stock.
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a next-generation biopharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the traditional drug development model. By leveraging an asset-centric R&D approach at scale, Centessa is advancing a robust pipeline of highly validated programs led by industry-leading teams. Each program is managed by a Centessa subsidiary and supported by a centralized infrastructure and executive management team.
The company’s clinical-stage assets include:
- SerpinPC - A novel treatment for Hemophilia A and B, currently in Phase 2b trials. SerpinPC is a subcutaneously administered inhibitor of APC, aiming to provide effective treatment irrespective of severity or inhibitor status.
- LB101 - A cutting-edge PD-L1xCD47 LockBody, targeting solid tumors. LB101 is currently in a Phase 1/2a clinical trial, designed to selectively drive potent effector functions to the tumor micro-environment while minimizing systemic toxicity.
- ORX750 - An orally administered, highly selective orexin receptor 2 (OX2R) agonist for Narcolepsy Type 1 (NT1) and other sleep disorders, currently in its Phase 1 clinical study.
- MGX292 - Targeting Pulmonary Arterial Hypertension (PAH).
- Undisclosed programs targeting solid tumors.
Recent Achievements include:
- Phase 2b study PRESent-3 of SerpinPC showing promising preliminary results.
- FDA Fast Track designation for SerpinPC in treating Hemophilia B.
- Progress in LB101's Phase 1/2a clinical trial.
- Launch of the Phase 1 study for ORX750, with initial proof-of-concept data in sleep-deprived healthy volunteers expected later this year.
Centessa’s innovative approach and comprehensive pipeline aim to deliver transformational medicines to patients, setting a new standard of care. For more information, visit their official website at http://www.centessa.com/.
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) presented additional data from the third year of the Phase 2a study of SerpinPC for the treatment of hemophilia at the American Society of Hematology (ASH) Annual Meeting. The data showed a 96% reduction in the median all-bleed annualized bleeding rate (ABR) from the prospective baseline, reinforcing the favorable safety and tolerability profile of SerpinPC. No thromboembolic events or treatment-related sustained elevations of D-dimer were observed during the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA): Ongoing studies for hemophilia B treatment, new data at ASH Annual Meeting, preclinical data on narcolepsy treatment presented at World Sleep Congress, financial results and business highlights for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals announced that new data from the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia will be presented at the 65th ASH Annual Meeting. SerpinPC is an investigational inhibitor of activated protein C in registrational studies for hemophilia B. The Phase 2a study is investigating the safety, tolerability, pharmacokinetics, and efficacy of SerpinPC in male participants with severe hemophilia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The study is a Phase 2b, global, open-label study to investigate the efficacy and safety of subcutaneous dosing of SerpinPC. The primary efficacy endpoint is the rate of treated bleeds compared to the first 24 weeks of treatment with SerpinPC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that its management team will participate in two upcoming investor conferences: Jefferies London Healthcare Conference on November 15, 2023, in London, and Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023, in Miami, FL. Access to live webcasts and archived recordings will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals announces new preclinical data on ORX750, a potential treatment for narcolepsy and sleep-wake disorders. The data show significant activity at low doses of ORX750 in translational models of narcolepsy type 1 (NT1) and other sleep-wake disorders. Clinical proof of concept data is planned for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
Rhea-AI Summary
Centessa Pharmaceuticals announces the appointment of April Dovholuk and Ellie Im to its executive team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
-
Rhea-AI Summary
Centessa Pharmaceuticals announces oral presentation of preclinical data for ORX750 at World Sleep Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
FAQ
What is the current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
The current stock price of Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is $17.16 as of December 20, 2024.
What is the market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA)?
The market cap of Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is approximately 2.3B.
What does Centessa Pharmaceuticals specialize in?
Centessa Pharmaceuticals specializes in developing transformational medicines through an asset-centric R&D model, focusing on treatments for hemophilia, solid tumors, and sleep-wake disorders.
Where is Centessa Pharmaceuticals headquartered?
Centessa Pharmaceuticals is headquartered in Cambridge, Massachusetts.
What is SerpinPC?
SerpinPC is a subcutaneously administered inhibitor of APC in clinical trials for treating Hemophilia A and B, aiming to provide effective treatment regardless of severity or inhibitor status.
What stage is LB101 in?
LB101, a PD-L1xCD47 LockBody targeting solid tumors, is currently in a Phase 1/2a clinical trial.
What is the focus of ORX750?
ORX750 is an orally administered, highly potent orexin receptor 2 (OX2R) agonist aimed at treating Narcolepsy Type 1 (NT1) and other sleep-wake disorders, currently in Phase 1 clinical study.
Has SerpinPC received any special designations?
Yes, SerpinPC has received Fast Track designation from the FDA for treating Hemophilia B.
What kind of development model does Centessa Pharmaceuticals use?
Centessa Pharmaceuticals utilizes an asset-centric R&D model, where each program is managed by a subsidiary and supported by centralized infrastructure and management.
What other programs are in Centessa's pipeline?
In addition to SerpinPC, LB101, and ORX750, Centessa is developing MGX292 for Pulmonary Arterial Hypertension and has undisclosed programs targeting solid tumors.
What recent achievements has Centessa Pharmaceuticals made?
Recent achievements include promising preliminary results from the Phase 2b study of SerpinPC, FDA Fast Track designation for SerpinPC, progress in LB101's Phase 1/2a trial, and the initiation of the Phase 1 study for ORX750 with expected proof-of-concept data later this year.
How can I find more information about Centessa Pharmaceuticals?
For more detailed information, you can visit Centessa Pharmaceuticals' official website at http://www.centessa.com/.
Centessa Pharmaceuticals plc American Depositary Shares
Nasdaq:CNTA
CNTA Rankings
CNTA Stock Data
2.30B
114.15M
1.32%
92.52%
1.85%
Biotechnology
Pharmaceutical Preparations
United States of America
ALTRINCHAM, CHESHIRE